Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 1156 AL 1170

Management of fracture risk in Parkinson's: A revised algorithm and focused review of treatments

Henderson EJ, Lyell V, Bhimjiyani A, Amin J, Kobylecki C, Gregson CL.

Parkinsonism Relat Disord. 2019 Jul;64:181-187. doi: 10.1016/j.parkreldis.2019.03.021. Epub 2019 Apr 8.

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease

Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-Ebo DM, Zhao P, Oh C.

Parkinsonism Relat Disord. 2019 Jul;64:175-180. doi: 10.1016/j.parkreldis.2019.03.026. Epub 2019 Mar 30.

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers

Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, Kim J, Yoo S, Chung YT, Lee JM, Cho DY.

Drug Des Devel Ther. 2019 Mar 29;13:1011-1022. doi: 10.2147/DDDT.S198753. eCollection 2019.

Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson's disease

Miller S, Muqit MMK.

Neurosci Lett. 2019 Jul 13;705:7-13. doi: 10.1016/j.neulet.2019.04.029. Epub 2019 Apr 14.

Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews

Armstrong MJ, Rastgardani T, Gagliardi AR, Marras C.

PLoS One. 2019 Apr 18;14(4):e0215384. doi: 10.1371/journal.pone.0215384. eCollection 2019.

Prioritized brain selenium retention and selenoprotein expression: Nutritional insights into Parkinson's disease

Zhang X, Liu RP, Cheng WH, Zhu JH.

Mech Ageing Dev. 2019 Jun;180:89-96. doi: 10.1016/j.mad.2019.04.004. Epub 2019 Apr 15.

Cancer and the Dopamine D(2) Receptor: A Pharmacological Perspective

Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ.

J Pharmacol Exp Ther. 2019 Jul;370(1):111-126. doi: 10.1124/jpet.119.256818. Epub 2019 Apr 18.

Ceramides in Parkinson's Disease: From Recent Evidence to New Hypotheses

Plotegher N, Bubacco L, Greggio E, Civiero L.

Front Neurosci. 2019 Apr 2;13:330. doi: 10.3389/fnins.2019.00330. eCollection 2019.

In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies

Marvian AT, Koss DJ, Aliakbari F, Morshedi D, Outeiro TF.

J Neurochem. 2019 Sep;150(5):535-565. doi: 10.1111/jnc.14707. Epub 2019 May 15.

Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies

Venkatramani A, Panda D.

Int J Biol Macromol. 2019 Jul 15;133:473-483. doi: 10.1016/j.ijbiomac.2019.04.120. Epub 2019 Apr 17.

Selective vulnerability in α-synucleinopathies

Alegre-Abarrategui J, Brimblecombe KR, Roberts RF, Velentza-Almpani E, Tilley BS, Bengoa-Vergniory N, Proukakis C.

Acta Neuropathol. 2019 Nov;138(5):681-704. doi: 10.1007/s00401-019-02010-2. Epub 2019 Apr 20.

The Neuropsychiatry of Parkinson Disease: A Perfect Storm

Weintraub D, Mamikonyan E.

Am J Geriatr Psychiatry. 2019 Sep;27(9):998-1018. doi: 10.1016/j.jagp.2019.03.002. Epub 2019 Mar 9.

Emerging drugs for progressive supranuclear palsy

Giagkou N, Stamelou M.

Expert Opin Emerg Drugs. 2019 Jun;24(2):83-92. doi: 10.1080/14728214.2019.1609450. Epub 2019 May 20.

Revelation of early repolarization by eliminating accessory pathway in manifest Wolff-Parkinson-White syndrome: A case report

Nauchi M, Sakai T, Sugisaki Y, Ito Y.

J Arrhythm. 2019 Feb 15;35(2):300-302. doi: 10.1002/joa3.12166. eCollection 2019 Apr.

Pseudo-Ventricular Tachycardia, Pseudo-Atrial Fibrillation, and Pseudo-Atrial Flutter in a Patient With Parkinson Disease: Two's Company, Three's a Crowd

Osman W, Hanson M, Baranchuk A.

JAMA Intern Med. 2019 Jun 1;179(6):824-826. doi: 10.1001/jamainternmed.2019.0746.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias